• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• Twitter
• Newsletter

Advertisement

Organisation › Details

Bristol-Myers Squibb Co. (BMS) (NYSE: BMY)

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook and Instagram. Celgene and Juno Therapeutics are wholly owned subsidiaries of Bristol-Myers Squibb Company. In certain countries outside the U.S., due to local laws, Celgene and Juno Therapeutics are referred to as, Celgene, a Bristol Myers Squibb company and Juno Therapeutics, a Bristol Myers Squibb company. *

 

	Start	1989-10-04 merged
	Group	Bristol-Myers Squibb (BMS) (Group)
	Industry	pharmaceutical
	Region	New York, NY
	Country	United States (USA)
	Street	430 East 29th Street 14th Floor
	City	10016 New York, NY
	Tel	+1-212-546-4000
		Address record changed: 2020-12-02
Basic data	Employees	H: 10,001 to 50,00 (2018-12-31)
	Currency	USD
	Annual sales	22,561,000,000 (revenue, total, consolidated (2018) 2018-12-31)
	Profit	4,947,000,000 (2018-12-31)
	Cash	6,911,000,000 (2018-12-31)
		* Document for �About Section�:
		Record changed: 2021-09-21

Advertisement

More documents for Bristol-Myers Squibb (BMS) (Group)

• [1] Cardior Pharmaceuticals GmbH. (8/25/21). "Press Release: Cardior Raises €64 M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Disease". Hanover....
• [2] Bristol-Myers Squibb Company. (8/19/21). "Press Release: Bristol Myers Squibb Receives European Commission Approval for Abecma (Idecabtagene Vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed and Refractory Multiple Myeloma". Princeton, NJ....
• [3] Bristol-Myers Squibb Company. (8/3/21). "Press Release: Bristol Myers Squibb Completes Sale of Manufacturing Facility in Couvet, Switzerland". New York, NY....
• [4] Exscientia Ltd.. (5/19/21). "Press Release: Exscientia Announces Multi-target, AI-driven Drug Discovery Collaboration with Bristol Myers Squibb"....
• [5] Droia Ventures. (5/11/21). "Press Release: Droia Ventures Raises a New Fund of EUR 220 Million to Target Genetic Diseases and Expands Leadership Team with George Golumbeski". Brussels....
• [6] Exscientia Ltd.. (4/27/21). "Press Release: Exscientia Announces Investment of up to $525M"....
• [7] Gyroscope Therapeutics Ltd.. (3/1/21). "Press Release: Gyroscope Therapeutics Appoints Jessica Stitt as Chief Financial Officer". London....
• [8] Evotec SE. (12/17/20). "Press Release: Evotec Achieves Key Milestones in Its Collaboration with Bristol Myers Squibb on Targeted Protein Degradation". Hamburg....
• [9] Evotec SE. (10/8/20). "Press Release: Evotec Achieves Milestone in Neurodegeneration Collaboration with Bristol Myers Squibb". Hamburg....
• [10] BioGeneration Ventures B.V.. (6/24/20). "Press Release: BioGeneration Ventures Closes BGV IV Fund at €105 Million". Naarden....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2021. Made in Germany.